QuickLinks -- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):December 23, 2004
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts
(State or other jurisdiction
of incorporation or organization) | | 0-14680
(Commission
File Number) | | 06-1047163
(IRS Employer
Identification Number) |
500 Kendall Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:(617) 252-7500
Item 8.01 Other Events.
As we reported on our current report on Form 8-K dated December 20, 2004 and filed with the SEC on December 21, 2004, on December 20, 2004, we completed the acquisition of ILEX Oncology, Inc., a publicly held Delaware corporation, pursuant to the terms of an Agreement and Plan of Merger dated as of February 26, 2004 among us, two of our wholly-owned subsidiaries (GLBC Corp. and GLBC LLC), and ILEX.
We are filing this report to include the unaudited, pro forma combined financial information which describes the pro forma effect of our transaction with ILEX on our statements of operations for the year ended December 31, 2003 and the nine months ended September 30, 2004, as if the transaction had occurred on January 1, 2003, and our balance sheet as of September 30, 2004, as if the transaction had occurred on this date.
Item 9.01. Financial Statements and Exhibits.
- (c)
- Exhibits:
| 99.1 | | Unaudited, pro forma combined financial information which describes the pro forma effect of our transaction with ILEX on our statements of operations for the year ended December 31, 2003 and the nine months ended September 30, 2004, as if the transaction had occurred on January 1, 2003, and our balance sheet as of September 30, 2004, as if the transaction had occurred on this date. Filed herewith. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | GENZYME CORPORATION |
|
|
By: |
/s/ MICHAEL S. WYZGA
Michael S. Wyzga
Executive Vice President, Finance, Chief Financial Officer, and Chief Accounting Officer |
DATE: December 23, 2004
EXHIBIT INDEX
EXHIBIT
NO.
| | DESCRIPTION
|
|---|
| 99.1 | | Unaudited, pro forma combined financial information which describes the pro forma effect of our transaction with ILEX on our statements of operations for the year ended December 31, 2003 and the nine months ended September 30, 2004, as if the transaction had occurred on January 1, 2003, and our balance sheet as of September 30, 2004, as if the transaction had occurred on this date. Filed herewith. |
QuickLinks
SIGNATUREEXHIBIT INDEX
